Cannabics Pharmaceuticals - Developing cannabinoid-based therapies
Cannabics develops cannabinoid-based, tumour reducing therapies. Its bioinformatics platform evaluates the efficacy of thousands of cannabinoid compounds on various cancers. In addition, it has recently launched a psychedelic inspired research programme focused on neuropsychiatric disorders. Its most advanced therapies target the $18bn colorectal cancer market, with human clinical trials planned to commence in 2022. Earlier-stage therapies target breast cancer, prostate cancer and melanomas. Cannabics has five granted patents and 20 patents pending.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.